FDA clears Aletta robot for autonomous blood draws

Aletta's clearance marks a milestone in robotic phlebotomy, a field explored for decades by academic groups and startups, though few reached commercial deployment. The device builds on prior research at Rutgers, and earlier attempts like VascuLogic did not survive, while companies like ROPHAI and MagicNurse continue work in the space. The FDA decision follows European regulators, who authorized the device two years earlier, giving Vitestro a head start in gathering real-world data.

A key question is whether Aletta's imaging works equally well for all skin tones, given the history of optical devices like pulse oximeters underperforming for people with darker skin. Vitestro argues its ultrasound sensor is "skin-tone agnostic" and cites unpublished data, but clinical chemists have called for independent evidence. Additionally, sample quality beyond red blood cell damage remains to be rigorously tested, with a U.S.-based trial planned next year.

The stakes are concrete for clinical labs struggling with nearly 25 percent annual turnover among phlebotomists. If Aletta can consistently free up staff, it could address long-standing capacity bottlenecks. But broader adoption likely hinges on whether Vitestro can provide the kind of published, independent data that addresses the concerns raised by experts in this report.